adyn vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 40)
adyn logo

adyn

EmergingHealthcare

General

Precision birth control test using hormone and genetic data to personalize contraceptive selection; $2.65M from Lux Capital and M13 addressing trial-and-error that leaves millions on wrong contraceptives.

AI VisibilityBeta
Overall Score
C40
Category Rank
#385 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
43
Perplexity
35
Gemini
37

About

adyn is a precision medicine company developing personalized birth control solutions through at-home testing kits that analyze hormone levels and genetic risk factors — enabling individuals to choose hormonal contraceptives based on their own biology rather than trial-and-error, addressing a gap where most people cycle through multiple birth control options over years to find what works without causing intolerable side effects. Founded in 2019 and a Y Combinator graduate, adyn raised $2.65 million in seed funding co-led by Lux Capital and M13, with the Birth Control Optimization Test positioned as the first biology-based test for contraceptive personalization.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

40
Overall Score
93
#385
Category Rank
#1
75
AI Consensus
80
stable
Trend
up
43
ChatGPT
94
35
Perplexity
89
37
Gemini
94
43
Claude
92
35
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.